These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22363037)

  • 1. Palliative chemotherapy for malignant ascites secondary to ovarian cancer.
    Malayev Y; Levene R; Gonzalez F
    Am J Hosp Palliat Care; 2012 Nov; 29(7):515-21. PubMed ID: 22363037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
    Hamilton CA; Maxwell GL; Chernofsky MR; Bernstein SA; Farley JH; Rose GS
    Gynecol Oncol; 2008 Dec; 111(3):530-2. PubMed ID: 18561992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
    Lowery WJ; Lowery AW; Barnett JC; Lopez-Acevedo M; Lee PS; Secord AA; Havrilesky L
    Gynecol Oncol; 2013 Sep; 130(3):426-30. PubMed ID: 23769759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of malignant ascites after intraperitoneal chemotherapy in women with carcinoma of the ovary.
    Lind SE; Cashavelly B; Fuller AF
    Surg Gynecol Obstet; 1988 Jun; 166(6):519-22. PubMed ID: 3375962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients.
    Kayl AE; Meyers CA
    Curr Opin Obstet Gynecol; 2006 Feb; 18(1):24-8. PubMed ID: 16493256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy.
    Patriti A; Cavazzoni E; Graziosi L; Pisciaroli A; Luzi D; Gullà N; Donini A
    Surg Laparosc Endosc Percutan Tech; 2008 Aug; 18(4):426-8. PubMed ID: 18716551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future options in the treatment of malignant ascites in ovarian cancer.
    Woopen H; Sehouli J
    Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
    Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML
    Gynecol Oncol; 2021 May; 161(2):374-381. PubMed ID: 33637349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathogenesis and management of refractory malignant ascites].
    Saâda E; Follana P; Peyrade F; Mari V; François E
    Bull Cancer; 2011 Jun; 98(6):679-87. PubMed ID: 21636346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative and end-of-life care for patients with ovarian cancer.
    Radwany SM; von Gruenigen VE
    Clin Obstet Gynecol; 2012 Mar; 55(1):173-84. PubMed ID: 22343236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites.
    Garofalo A; Valle M; Garcia J; Sugarbaker PH
    Eur J Surg Oncol; 2006 Aug; 32(6):682-5. PubMed ID: 16631341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive management of recurrent ovarian cancer--the challenge of individualizing cancer therapy illustrated by a case report.
    Kieback DG; Einzmann T; Labinsky E; Fischer DC; Niebergall H; Hasenburg A
    Onkologie; 2004 Aug; 27(4):393-7. PubMed ID: 15347897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of chemotherapy with palliative intent in the last 30 days of life: the balance between palliation and chemotherapy.
    Zdenkowski N; Cavenagh J; Ku YC; Bisquera A; Bonaventura A
    Intern Med J; 2013 Nov; 43(11):1191-8. PubMed ID: 23870085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer care: a case study in determined living.
    Umlauf RL; Orloff GJ
    Onkologie; 2006 Feb; 29(1-2):27-9. PubMed ID: 16514251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
    Patnaik A; Doyle C; Oza AM
    Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life for patients with epithelial ovarian cancer.
    Sun CC; Ramirez PT; Bodurka DC
    Nat Clin Pract Oncol; 2007 Jan; 4(1):18-29. PubMed ID: 17183353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.
    Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF
    Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal chemotherapy for women with epithelial ovarian cancer.
    Trimble EL; Thompson S; Christian MC; Minasian L
    Oncologist; 2008 Apr; 13(4):403-9. PubMed ID: 18448554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.